Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic V, Jardine MJ, Neal B, et al.
N Engl J Med. 2019;380(24):2295-306
Leggi
Breaking news
Marked Improvement in Hba1c Following Commencement of Flash Glucose Monitoring in People with Type 1 Diabetes
Tyndall V, Stimson RH, Zammitt NN, et al.
Diabetologia. Pub. online 9 June 2019
Leggi
Cardiovascular Corner – Low Lipids, Metformin, and Plant-Based Diets
Abbasi J
JAMA. Pub. online 12 June 2019
Leggi
Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients with and Without Diabetes Mellitus
Gyldenkerne C, Olesen KKW, Jensen LO, et al.
The American Journal of Cardiology. Pub. online 6 June 2019
Leggi
Vitamin D Supplementation and Prevention of Type 2 Diabetes
Pittas AG, Dawson-Hughes B, Sheehan P, et al.
N Engl J Med. Pub. online 7 June 2019
Leggi
Cardiovascular Disease Risk across a Spectrum of Adverse Plasma Lipid Combinations by Sex and Glycemic Status
Liu X, Yang Y, ,Kang F, et al.
The American Journal of Cardiology. Pub. online 6 June 2019
Leggi
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Pollock C, Stefánsson B, Reyner D, et al.
Lancet Diabetes Endocrinol. 2019;7(6):429-41
Leggi
Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial
Bosi E, Choudhary P, de Valk HW, et al.
Lancet Diabetes Endocrinol. 2019;7(6):462-72
Leggi
Predicting individual treatment response in diabetes
Heerspink HJL
Lancet Diabetes Endocrinol. 2019;7(6):415-7
Leggi
Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study
Gong Q, Zhang P, Wang J, et al.
Lancet Diabetes Endocrinol. 2019;7(6):452-61
Leggi